ライフサイエンスコーパス: ursodeoxycholic acid

1 limit of normal (ULN) despite treatment with ursodeoxycholic acid.

2 maining 17% of bile acids were identified as ursodeoxycholic acid.

3 re commonly in the 21 patients randomized to ursodeoxycholic acid.

4 c acid > cholic acid > hyodeoxycholic acid > ursodeoxycholic acid.

5 apidly triggered by a diet supplemented with ursodeoxycholic acid.

6 r in patients with an inadequate response to ursodeoxycholic acid.

7 ry cirrhosis who had inadequate responses to ursodeoxycholic acid.

8 adequate response to first-line therapy with ursodeoxycholic acid.

9 All patients were treated with ursodeoxycholic acid.

10 be attributable to liver transplantation or ursodeoxycholic acid.

11 iet or control diet plus cholic acid (1%) or ursodeoxycholic acid (1%) for 10 days.

12 e, or incomplete response were randomized to ursodeoxycholic acid (13-15 mg/kg daily) or placebo for

13 lic acid (3alpha-OH, 7alpha-OH, 12alpha-OH), ursodeoxycholic acid (3alpha-OH, 7beta-OH), and lithocho

14 colonic mucosal tissue in vitro In contrast, ursodeoxycholic acid (50-200 microM) inhibited both basa

15 Taurine-conjugated ursodeoxycholic acid, a hydrophilic bile acid, similarly

16 4-Phenyl butyric acid and taurine-conjugated ursodeoxycholic acid alleviated ER stress in cells and w

17 mittance and following treatment with either ursodeoxycholic acid alone (10 mg/kg thrice daily, n = 1

18 lus ursodeoxycholic acid was not superior to ursodeoxycholic acid alone for the prevention or occlusi

19 hemical response occurred under therapy with ursodeoxycholic acid, alone or in combination with immun

20 Of note, both ursocholanic acid and ursodeoxycholic acid also rescued mitochondrial function

21 acid, radioactivity was detected in both the ursodeoxycholic acid and chenodeoxycholic acid fractions

22 ntial forms of therapy, including the use of ursodeoxycholic acid and cholecystokinin.

23 alysis in 168 patients with PSC treated with ursodeoxycholic acid and followed up from November 2004

24 changes in the pharmacokinetic parameters of ursodeoxycholic acid and its conjugates.

25 activity calculation, and the routine use of ursodeoxycholic acid and low-dose steroids (modified pro

26 were similar before and after treatment with ursodeoxycholic acid and no different than after placebo

27 e drugs that antagonize BS toxicity, such as ursodeoxycholic acid and nor-ursodeoxycholic acid, may b

28 Ursodeoxycholic acid and S-adenosyl-L-methionine are the

29 Ursodeoxycholic acid and S-adenosylmethionine are anti-f

30 The combination of ursodeoxycholic acid and simvastatin for the resolution

31 might be reduced by early enteral feedings, ursodeoxycholic acid, and cholecystokinin-octapeptide.

32 its were corrected by oral administration of ursodeoxycholic acid, and the addition of an oral proton

33 compound ursolic acid and the licensed drug ursodeoxycholic acid are chemically closely related to u

34 results indicate that substantial amounts of ursodeoxycholic acid are formed in patients treated with

35 Corticosteroids or ursodeoxycholic acid are treatment options for patients

36 To evaluate the efficacy of ursodeoxycholic acid as adjunctive therapy in type 1 aut

37 acid as a naturally occurring compound, and ursodeoxycholic acid as an already licensed drug as prom

38 r, phenylbutyric acid and taurine-conjugated ursodeoxycholic acid attenuated HNE-induced leukocyte ro

39 Ursodiol (ursodeoxycholic acid) benefits patients with primary bil

40 d by restoring biliary secretion with 24-nor-ursodeoxycholic acid but were significantly reduced by o

41 Use of ursodeoxycholic acid can improve alkaline phosphatase an

42 We conclude that ursodeoxycholic acid can improve certain laboratory test

43 Moreover, ursodeoxycholic acid can reduce apoptosis by minimizing

44 Ursodeoxycholic acid caused a dose-dependent decrease in

45 , sitosterol, cholic acid, deoxycholic acid, ursodeoxycholic acid, cholestyramine, bile fistula, lova

46 In contrast, ursodeoxycholic acid did not exhibit any of these effect

47 Bile acids deoxycholic acid and ursodeoxycholic acid differentially regulate human beta-

48 holic acid, the specific activity of biliary ursodeoxycholic acid exceeded the specific activity of c

49 a multicenter randomized trial of high dose ursodeoxycholic acid for PSC.

50 Maternal management is symptomatic with ursodeoxycholic acid; for the fetus, however, this is a

51 important, because effective treatment with ursodeoxycholic acid has been shown to halt disease prog

52 Ursodeoxycholic acid has the potency to suppress eosinop

53 was confirmed for both ursocholanic acid and ursodeoxycholic acid in a Parkin-deficient neuronal mode

54 Initial results from high-dose ursodeoxycholic acid in halting disease progression, how

55 periority of 24-norursodeoxycholic acid over ursodeoxycholic acid in reducing histological disease pr

56 However, ursodeoxycholic acid increased activity 84% (P < .05) an

57 experiments provide the first evidence that ursodeoxycholic acid is effective for preventing adenoma

58 Ursodeoxycholic acid may have a role as a colorectal and

59 Oral administration of ursodeoxycholic acid may improve bile flow and reduce ga

60 of multiple cholesterol stone formation, and ursodeoxycholic acid may partially halt the formation of

61 xicity, such as ursodeoxycholic acid and nor-ursodeoxycholic acid, may be effective at all disease st

62 The chemoprevention effects of ursodeoxycholic acid on colorectal dysplasia await furth

63 ng the effects of deoxycholic acid (DCA) and ursodeoxycholic acid on the expression and release of Hb

64 ) occurred as commonly in patients receiving ursodeoxycholic acid or placebo.

65 id (deoxycholic acid, chenodeoxycholic acid, ursodeoxycholic acid, or glycochenodeoxycholic acid) in

66 Despite therapy with ursodeoxycholic acid, prednisone, and then tacrolimus, h

67 Ursodeoxycholic acid prevents eosinophilic degranulation

68 Ursodeoxycholic acid remains the most studied medical tr

69 C, which is unrelated to disease severity or ursodeoxycholic acid response, is significant and comple

70 el insights into the mechanisms of action of ursodeoxycholic acid should advance our understanding of

71 ears following biopsy, including response to ursodeoxycholic acid, show identical changes to patients

72 ies, showed identical treatment responses to ursodeoxycholic acid, similar rates and types of nonhepa

73 Ursodeoxycholic acid strongly promoted interleukin (IL)-

74 ewed interest in developing therapies beyond ursodeoxycholic acid that are aimed at both slowing dise

75 The formation of ursodeoxycholic acid, the 7 beta-hydroxy epimer of cheno

76 Ursodeoxycholic acid, the standard first-line treatment

77 dults with PBC and an inadequate response to ursodeoxycholic acid therapy (i.e., alkaline phosphatase

78 The precise role of weight reduction and ursodeoxycholic acid therapy in the favorable alteration

79 cirrhosis who had an inadequate response to ursodeoxycholic acid therapy.

80 Patients maintained their existing dose of ursodeoxycholic acid throughout the study.

81 Ursodeoxycholic acid-treated DCs have less capacity than

82 Ursodeoxycholic acid treatment of OVA-sensitized mice pr

83 18:0/18:1), PS(14:1/14:0), dihydroxyacetone, ursodeoxycholic acid, tryptophan, L-valine, cycloserine,

84 assigned to ceftriaxone also received 300 mg ursodeoxycholic acid twice daily and those assigned to p

85 Ursodeoxycholic acid (UDC) and hyocholic acid (HC) feedi

86 d, double-blind, placebo-controlled trial of ursodeoxycholic acid (UDCA) (10-12 mg/kg/d) taken as a s

87 Intriguingly, treatment with ursodeoxycholic acid (UDCA) ameliorates eosinophilia as

88 Oral administration of ursodeoxycholic acid (UDCA) and cholesterol causes bile

89 uate the safety and estimate the efficacy of ursodeoxycholic acid (UDCA) and clofibrate in the treatm

90 We identified ursodeoxycholic acid (UDCA) and deoxycholic acid (DCA) a

91 patients with AMA-negative PBC treated with ursodeoxycholic acid (UDCA) and/or liver transplantation

92 igation (BDL) in mice and how treatment with ursodeoxycholic acid (UDCA) and/or S-adenosylmethionine

93 Ursodeoxycholic acid (UDCA) can protect hepatocytes from

94 acid (DCA), chenodeoxycholic acid (CDCA) or ursodeoxycholic acid (UDCA) caused sustained MAPK activa

95 s are inconclusive regarding the efficacy of ursodeoxycholic acid (UDCA) for treating primary scleros

96 Ursodeoxycholic acid (UDCA) has been shown in small, ope

97 Ursodeoxycholic acid (UDCA) has been shown to be a safe

98 Ursodeoxycholic acid (UDCA) has been suggested to be of

99 Ursodeoxycholic acid (UDCA) has shown effectiveness as a

100 Ursodeoxycholic acid (UDCA) improves liver function in p

101 d-line treatment for PBC in combination with ursodeoxycholic acid (UDCA) in adults with an inadequate

102 more, we investigated the mechanism by which ursodeoxycholic acid (UDCA) inhibits LXR-induced lipogen

103 Ursodeoxycholic acid (UDCA) is a beneficial medical ther

104 Ursodeoxycholic acid (UDCA) is a safe and effective medi

105 Ursodeoxycholic acid (UDCA) is a safe and effective medi

106 Ursodeoxycholic acid (UDCA) is a safe and effective trea

107 Ursodeoxycholic acid (UDCA) is no longer recommended for

108 Ursodeoxycholic acid (UDCA) is the only approved treatme

109 Ursodeoxycholic acid (UDCA) is the only approved treatme

110 Despite limited benefits, ursodeoxycholic acid (UDCA) is the only Food and Drug Ad

111 Ursodeoxycholic acid (UDCA) is the only known beneficial

112 Ursodeoxycholic acid (UDCA) is used for the treatment of

113 Ursodeoxycholic acid (UDCA) is used to treat primary bil

114 Ursodeoxycholic acid (UDCA) is widely used for cholangio

115 Standard doses of ursodeoxycholic acid (UDCA) lead to improvements in bioc

116 This study sought to assess the effects of ursodeoxycholic acid (UDCA) on endothelial function and

117 d a meta-analysis to evaluate the effects of ursodeoxycholic acid (UDCA) on pruritus, liver test resu

118 Ursodeoxycholic acid (UDCA) or S-adenosylmethionine (SAM

119 We have also shown that ursodeoxycholic acid (UDCA) prevented AOM-induced colon

120 Ursodeoxycholic acid (UDCA) prevents the formation of ga

121 The hydrophilic bile salt ursodeoxycholic acid (UDCA) protects against the membran

122 Ursodeoxycholic acid (UDCA) protects cells from the apop

123 rmine the influence of IBD and the effect of ursodeoxycholic acid (UDCA) therapy on the course of the

124 ed that feeding the cytoprotective bile acid ursodeoxycholic acid (UDCA) to rats resulted in signific

125 High-dose (28-30 mg/kg/day) ursodeoxycholic acid (UDCA) treatment improves serum liv

126 GF mdr2(-/-) mice and abrogated in vitro by ursodeoxycholic acid (UDCA) treatment.

127 d, double-blind, placebo-controlled trial of ursodeoxycholic acid (UDCA) versus placebo.

128 ), and effects of treatment with 4-PB and/or ursodeoxycholic acid (UDCA) were assessed.

129 e of them were treated in the follow up with ursodeoxycholic acid (UDCA), eight received during a tri

130 diagnosis reports, response to therapy with ursodeoxycholic acid (UDCA), laboratory results, and sym

131 Ursodeoxycholic acid (UDCA), methotrexate, and colchicin

132 frequently progresses despite treatment with ursodeoxycholic acid (UDCA), the only approved therapy.

133 eutic option available for these patients is ursodeoxycholic acid (UDCA), which slows the progression

134 The biochemical response to ursodeoxycholic acid (UDCA)--so-called "treatment respon

135 nthesis and steady-state pharmacokinetics of ursodeoxycholic acid (UDCA).

136 ntional treatment with the natural bile acid ursodeoxycholic acid (UDCA).

137 stasis of pregnancy (ICP) and treatment with ursodeoxycholic acid (UDCA).

138 nged substantially with the introduoction of ursodeoxycholic acid (UDCA).

139 irrhosis (PBC) and an incomplete response to ursodeoxycholic acid (UDCA).

140 d in AC and was prevented by the hydrophilic ursodeoxycholic acid (UDCA).

141 ecifically, our approach involves the use of ursodeoxycholic acid (Urso) due to its ability to decrea

142 Sulindac was tested in combination with ursodeoxycholic acid (ursodiol), a naturally occurring 7

143 ar 50 mg/day, or seladelpar 200 mg/day while ursodeoxycholic acid was continued.

144 f 1 kg), and the finding that ofloxacin plus ursodeoxycholic acid was not superior to ursodeoxycholic

145 The ursodeoxycholic acid was synthesized from chenodeoxychol

146 Treatment responses to corticosteroids or ursodeoxycholic acid were poor.

147 NF-kappaB, an effect that was attenuated by ursodeoxycholic acid, whereas an NF-kappaB inhibitor, BM

148 Ursodeoxycholic acid, which in vivo is converted to its

149 Moreover, the hepatoprotective bile acid ursodeoxycholic acid, which reverses hydrophobic bile ac

150 ed drug in primary sclerosing cholangitis is ursodeoxycholic acid, which, despite a range of potentia

151 properties of hydrophilic bile acids such as ursodeoxycholic acid, with the distinct ability to speci